Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
This compares to the stock's 9.5% gain over the past four weeks. Travere Therapeutics' stock surged after the FDA approved Filspari for a second rare kidney disease, making it the first treatment for focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome and significantly expanding its market. The decision was backed by strong phase III data showing superior proteinuria reduction and kidney function benefits versus Avapro, reinforcing the drug's clinical efficacy. With immediate availability and a broader addressable population of more than 100,000 U.S. patients across FSGS and primary IgA nephropathy, investors reacted positively to the drug's enhanced commercial potential. This drug developer is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of +40.4%. Revenues are expected to be $128.11 million, up 56.8% from the year-ago quarter. While earnings and revenue growth expectations are important in
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views [Yahoo! Finance]Yahoo! Finance
- A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI's Landmark FDA Approval For FSGS [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Travere Therapeutics (TVTX) was upgraded by Piper Sandler from "neutral" to "overweight". They now have a $49.00 price target on the stock.MarketBeat
- Travere Therapeutics (TVTX) had its price target raised by Canaccord Genuity Group Inc. from $47.00 to $56.00. They now have a "buy" rating on the stock.MarketBeat
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- TVTX's page on the SEC website